SEACOAST trial suggests simvastatin plus extended-release niacin is significantly more effective than simvastatin alone for improving lipid profiles
The phase III SEACOAST trial suggests that a fixed-dose
combination of simvastatin and extended-release niacin is significantly more effective
than simvastatin alone for improving lipid profiles, according to a presentation
at the annual meeting of the American Heart Association.
The combination product included the manufacturer’s proprietary extended-release
niacin, NiaspanR.
The 24-week enrolled more than 600 patients with elevated non-HDL (type II
hyperlipidemia or mixed dyslipidemia) to compare simvastatin alone to a combination
of extended-release niacin combined with simvastatin. The study was designed to
evaluate the safety and efficacy of the combination following simvastatin monotherapy.
Patients randomized to the low-dose group received Niaspan 2000 mg/simvastatin
20 mg, Niaspan 1000 mg/simvastatin 20 mg, or simvastatin 20 mg. Patients in the
high-dose group received Niaspan 2000 mg/simvastatin 40 mg, Niaspan 1000 mg/simvastatin
40 mg or simvastatin 80 mg. Those in the simvastatin control groups received a
50 mg dose of immediate-release niacin to maintain blinding.
Patients in the low-dose group receiving combination treatment achieved 14-percent
(1000 mg/20 mg) and 23-percent (2000 mg/20 mg) reductions in non-high-density
cholesterol compared with a 7-percent reduction with 20 mg simvastatin therapy
alone.
Additionally, combination treatment resulted in significant improvements in
high-density cholesterol of 18 percent (1000 mg/20 mg) and 25 percent (2000 mg/20
mg) compared with 7 percent with 20 mg simvastatin alone. Similarly, significant
reductions in triglycerides of 27 percent (1000 mg/20 mg) and 38 percent (2000
mg/20 mg) were seen in those treated with combination therapy compared with a
15-percent reduction with simvastatin monotherapy.
In the high-dose group, patients treated with combination therapy showed similar
(non-inferior) improvements in non-high-density cholesterol of 11 percent (1000
mg/40 mg) and 17 percent (2000 mg/40 mg) compared with a 10-percent improvement
with 80 mg simvastatin therapy alone. Additionally, the high-dose combination
group demonstrated significant improvements in high-density cholesterol of 15
percent (1000 mg/40 mg) and 22 percent (2000 mg/40 mg) compared with a 1-percent
decrease for 80 mg simvastatin monotherapy. Triglyceride levels among the high-dose
combinations groups dropped 23 percent and 32 percent, respectively, in contrast
to a 0.3 percent increase in those randomized to 80 mg simvastatin monotherapy.
Treatment with the four different doses of niacin combined with simvastatin
for 24 weeks was well tolerated. There was no evidence for increased risk of hepatotoxicity
or myopathy with the combination.
Patients in the study treated with the low-dose combination containing 20
mg simvastatin had significantly better reductions in non-high-density lipoprotein
cholesterol compared with 20 mg simvastatin therapy alone, as well as significant
improvements in high-density cholesterol and triglyceride levels.
Patients who received the high-dose combination with 40 mg simvastatin experienced
reductions in non-high-density cholesterol comparable with 80 mg simvastatin alone,
as well as significantly better improvements in high-density cholesterol and triglycerides
than achieved with 80 mg simvastatin alone.
Flushing was the most commonly reported side effect associated with niacin.
It was generally mild and could be lessened by taking aspirin 30 minutes prior
to taking the medication at bedtime. Six percent of patients on the combination
discontinued therapy due to flushing compared with a 0.8 percent discontinuation
rate with simvastatin alone.
"Patients know that it's important to manage the "bad" cholesterol,
but it's essential to control HDL and triglyceride levels as well," said
Christie Ballantyne, MD, Baylor College of Medicine and Methodist DeBakey Heart
Center, Houston, Texas, and lead investigator on the study. "With the SEACOAST
study, SIMCOR provided comparable LDL lowering to simvastatin with significant
benefit in raising good cholesterol and lowering triglycerides. This type of combination
approach could be an important tool in treating patients with complex lipid disorders."
|